Duration 0 8 0 8 O
of 9 11 9 11 O
pink 12 16 12 16 B-chronic_disease
eye 17 20 17 20 I-chronic_disease
symptoms 21 29 21 29 O
: 29 30 29 30 O
No 31 33 31 33 O
more 34 38 34 38 O
than 39 43 39 43 O
4 44 45 44 45 B-upper_bound
days 46 50 46 50 I-upper_bound
in 51 53 51 53 O
first 54 59 54 59 O
affected 60 68 60 68 O
eye 69 72 69 72 O
Positive 73 81 73 81 O
immunoassay 82 93 82 93 O
test 94 98 94 98 O
AdenoPlus(TM 99 111 99 111 O
) 111 112 111 112 O
for 113 116 113 116 O
presence 117 125 117 125 O
of 126 128 126 128 O
adenovirus 129 139 129 139 O

Eye 0 3 140 143 B-treatment
surgery 4 11 144 151 I-treatment
in 12 14 152 154 O
the 15 18 155 158 O
last 19 23 159 163 B-upper_bound
3 24 25 164 165 I-upper_bound
months 26 32 166 172 I-upper_bound

Patients 0 8 173 181 O
will 9 13 182 186 O
be 14 16 187 189 O
18 17 19 190 192 B-lower_bound
years 20 25 193 198 I-lower_bound
and 26 29 199 202 O
older 30 35 203 208 O

Patients 0 8 209 217 O
with 9 13 218 222 O
history 14 21 223 230 O
of 22 24 231 233 O
herpes 25 31 234 240 B-chronic_disease
simplex 32 39 241 248 I-chronic_disease
infection 40 49 249 258 I-chronic_disease
or 50 52 259 261 O
corneal 53 60 262 269 B-chronic_disease
ulceration 61 71 270 280 I-chronic_disease

Sex 0 3 281 284 O
: 3 4 284 285 O
Pink 5 9 286 290 B-chronic_disease
eye 10 13 291 294 I-chronic_disease
{ 14 15 295 296 I-chronic_disease
adenoviral 15 25 296 306 I-chronic_disease
conjunctivitis 26 40 307 321 I-chronic_disease
( 41 42 322 323 I-chronic_disease
Ad 42 44 323 325 I-chronic_disease
- 44 45 325 326 I-chronic_disease
Cs 45 47 326 328 I-chronic_disease
) 47 48 328 329 I-chronic_disease
} 48 49 329 330 I-chronic_disease
occurs 50 56 331 337 O
with 57 61 338 342 O
equal 62 67 343 348 O
prevalence 68 78 349 359 O
in 79 81 360 362 O
males 82 87 363 368 B-gender
and 88 91 369 372 I-gender
females 92 99 373 380 I-gender
, 99 100 380 381 O
therefore 101 110 382 391 O
we 111 113 392 394 O
will 114 118 395 399 O
recruit 119 126 400 407 O
both 127 131 408 412 O
genders 132 139 413 420 O

